Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy

Medical Physics

Volumn 39, Issue 10, 2012, Pages 6118-6128

  Baechler, Sébastien ^a   Hobbs, Robert F ^b   Boubaker, Ariane ^a   Buchegger, Franz ^a   He, Bin ^b   Frey, Eric C ^b   Sgouros, George ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biological effective dose; kidney dosimetry; peptide receptor radionuclide therapy

Indexed keywords

DOSIMETRY; PEPTIDES; PLANNING; RADIOISOTOPES;

AMOUNT OF ACTIVITIES; BIOLOGICAL EFFECTIVE DOSE; DIFFERENT TREATMENTS; DOSE-VOLUME HISTOGRAMS; NUMBER OF CYCLES; RADIONUCLIDE THERAPY; THERAPEUTIC RADIONUCLIDES; TREATMENT PLANNING;

PATIENT TREATMENT;

EID: 84867315669     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.4752213     Document Type: Article

References (48)

1. D. J. Kwekkeboom, J. Mueller-Brand, G. Paganelli, L. B. Anthony, S. Pauwels, L. K. Kvols, T. M. O'Dorisio, R. Valkema, L. Bodei, M. Chinol, H. R. Maecke, and E. P. Krenning, Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs., J. Nucl. Med. 46 (Suppl. 1), 62S-66S (2005).
2. R. Valkema, M. De Jong, W. H. Bakker, W. A. Breeman, P. P. Kooij, P. J. Lugtenburg, F. H. De Jong, A. Christiansen, B. L. Kam, W. W. De Herder, M. Stridsberg, J. Lindemans, G. Ensing, and E. P. Krenning, Phase I study of peptide receptor radionuclide therapy with In-DTPAoctreotide: The Rotterdam experience., Semin. Nucl. Med. 32, 110-122 (2002). 10.1053/snuc/2002.31025
3. J. C. Reubi, H. R. Macke, and E. P. Krenning, Candidates for peptide receptor radiotherapy today and in the future., J. Nucl. Med. 46 (Suppl. 1), 67S-75S (2005).
4. D. J. Kwekkeboom, B. L. Kam, M. van Essen, J. J. Teunissen, C. H. van Eijck, R. Valkema, M. de Jong, W. W. de Herder, and E. P. Krenning, Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors., Endocr. Relat. Cancer 17, R53-R73 (2010). 10.1677/ERC-09-0078
5. J. P. Esser, E. P. Krenning, J. J. Teunissen, P. P. Kooij, A. L. van Gameren, W. H. Bakker, and D. J. Kwekkeboom, Comparison of (177)Lu-DOTA(0), Tyr(3)octreotate and (177)Lu-DOTA(0),Tyr(3)octreotide: Which peptide is preferable for PRRT, Eur. J. Nucl. Med. Mol. Imaging 33, 1346-1351 (2006). 10.1007/s00259-006-0172-9
6. B. Lambert, M. Cybulla, S. M. Weiner, C. Van De Wiele, H. Ham, R. A. Dierckx, and A. Otte, Renal toxicity after radionuclide therapy., Radiat. Res. 161, 607-611 (2004). 10.1667/RR3105
7. M. van Essen, E. P. Krenning, B. L. Kam, M. de Jong, R. Valkema, and D. J. Kwekkeboom, Peptide-receptor radionuclide therapy for endocrine tumors., Nat. Rev. Endocrinol. 5, 382-393 (2009). 10.1038/nrendo.2009.105
8. M. Cremonesi, F. Botta, A. Di Dia, M. Ferrari, L. Bodei, C. De Cicco, A. Rossi, M. Bartolomei, R. Mei, S. Severi, M. Salvatori, G. Pedroli, and G. Paganelli, Dosimetry for treatment with radiolabelled somatostatin analogues: A review., Q. J. Nucl. Med. Mol. Imaging 54, 37-51 (2010).
9. W. S. Snyder, M. R. Ford, G. G. Warner, and S. B. Watson, S," Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs: MIRD Pamphlet No. 11 (Society of Nuclear Medicine, New York, 1975).
10. L. G. Bouchet, W. E. Bolch, H. P. Blanco, B. W. Wessels, J. A. Siegel, D. A. Rajon, I. Clairand, and G. Sgouros, MIRD Pamphlet No. 19: Absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney., J. Nucl. Med. 44, 1113-1147 (2003).
11. R. Barone, F. Borson-Chazot, R. Valkema, S. Walrand, F. Chauvin, L. Gogou, L. K. Kvols, E. P. Krenning, F. Jamar, and S. Pauwels, Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship., J. Nucl. Med. 46 (Suppl. 1), 99S-106S (2005).
12. R. G. Dale, The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy., Br. J. Radiol. 58, 515-528 (1985). 10.1259/0007-1285-58-690-515
13. S. Baechler, R. F. Hobbs, A. R. Prideaux, R. L. Wahl, and G. Sgouros, Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry., Med. Phys. 35, 1123-1134 (2008). 10.1118/1.2836421
14. B. W. Wessels, M. W. Konijnenberg, R. G. Dale, H. B. Breitz, M. Cremonesi, R. F. Meredith, A. J. Green, L. G. Bouchet, A. B. Brill, W. E. Bolch, G. Sgouros, and S. R. Thomas, MIRD Pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy., J. Nucl. Med. 49, 1884-1899 (2008). 10.2967/jnumed.108.053173
15. A. R. Prideaux, H. Song, R. F. Hobbs, B. He, E. C. Frey, P. W. Ladenson, R. L. Wahl, and G. Sgouros, Three-dimensional radiobiologic dosimetry: Application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry., J. Nucl. Med. 48, 1008-1016 (2007). 10.2967/jnumed.106.038000
16. R. F. Hobbs, R. L. Wahl, M. A. Lodge, M. S. Javadi, S. Y. Cho, D. T. Chien, M. E. Ewertz, C. E. Esaias, P. W. Ladenson, and G. Sgouros, 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: Real-time treatment planning and methodologic comparison., J. Nucl. Med. 50, 1844-1847 (2009). 10.2967/jnumed.109.066738
17. J. A. Siegel, S. R. Thomas, J. B. Stubbs, M. G. Stabin, M. T. Hays, K. F. Koral, J. S. Robertson, R. W. Howell, B. W. Wessels, D. R. Fisher, D. A. Weber, and A. B. Brill, MIRD Pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates., J. Nucl. Med. 40, 37S-61S (1999).
18. S. Baechler, R. F. Hobbs, A. R. Prideaux, M. Recordon, A. Bischof-Delaloye, and G. Sgouros, Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan., Cancer Biother. Radiopharm. 23, 633-639 (2008). 10.1089/cbr.2008.0506
19. B. He, Y. Du, X. Y. Song, W. P. Segars, and E. C. Frey, A Monte Carlo and physical phantom evaluation of quantitative In-111SPECT., Phys. Med. Biol. 50, 4169-4185 (2005). 10.1088/0031-9155/50/17/018
20. H. M. Hudson and R. S. Larkin, Accelerated image-reconstruction using ordered subsets of projection data., IEEE Trans. Med. Imaging 13, 601-609 (1994). 10.1109/42.363108
21. D. J. Kadrmas, E. C. Frey, S. S. Karimi, and B. M. Tsui, Fast implementations of reconstruction-based scatter compensation in fully 3D SPECT image reconstruction., Phys. Med. Biol. 43, 857-873 (1998). 10.1088/0031-9155/ 43/4/014
22. M. G. Stabin, R. B. Sparks, and E. Crowe, OLINDAEXM: The second-generation personal computer software for internal dose assessment in nuclear medicine., J. Nucl. Med. 46, 1023-1027 (2005).
23. G. Sgouros and K. S. Kolbert, The three-dimensional internal dosimetry software package, 3D-ID., in Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine, edited by, H. Zaidi, and, G. Sgouros, (Institute of Physics, Philadelphia, PA, 2002), pp. 249-261.
24. R. F. Hobbs and G. Sgouros, Calculation of the biological effective dose (BED) for piece-wise defined dose-rate fits.., Med. Phys. 36, 904-907 (2009). 10.1118/1.3070587
25. A. R. Stahl, L. Freudenberg, A. Bockisch, and W. Jentzen, A novel view on dosimetry-related radionuclide therapy: Presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinoma., Eur. J. Nucl. Med. Mol. Imaging 36, 1147-1155 (2009). 10.1007/s00259-009-1077-1
26. L. Bodei, M. Cremonesi, M. Ferrari, M. Pacifici, C. M. Grana, M. Bartolomei, S. M. Baio, M. Sansovini, and G. Paganelli, Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors., Eur. J. Nucl. Med. Mol. Imaging 35, 1847-1856 (2008). 10.1007/s00259-008-0778-1
27. E. J. Rolleman, R. Valkema, M. de Jong, P. P. Kooij, and E. P. Krenning, Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine., Eur. J. Nucl. Med. Mol. Imaging 30, 9-15 (2003). 10.1007/s00259-002-0982-3
28. M. de Jong and E. Krenning, New advances in peptide receptor radionuclide therapy., J. Nucl. Med. 43, 617-620 (2002).
29. F. Jamar, R. Barone, I. Mathieu, S. Walrand, D. Labar, P. Carlier, J. de Camps, H. Schran, T. Chen, M. C. Smith, H. Bouterfa, R. Valkema, E. P. Krenning, L. K. Kvols, and S. Pauwels, 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)-a phase 1 clinical study: Pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion., Eur. J. Nucl. Med. Mol. Imaging 30, 510-518 (2003). 10.1007/s00259-003-1117-1
30. L. Bodei, M. Cremonesi, S. Zoboli, C. Grana, M. Bartolomei, P. Rocca, M. Caracciolo, H. R. Macke, M. Chinol, and G. Paganelli, Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study., Eur. J. Nucl. Med. Mol. Imaging 30, 207-216 (2003). 10.1007/s00259-002-1023-y
31. R. Valkema, S. A. Pauwels, L. K. Kvols, D. J. Kwekkeboom, F. Jamar, M. de Jong, R. Barone, S. Walrand, P. P. Kooij, W. H. Bakker, J. Lasher, and E. P. Krenning, Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate., J. Nucl. Med. 46 (Suppl. 1), 83S-91S (2005).
32. ICRP, Radiation Dose to Patients from Pharmaceuticals (Pergammon, 2009).
33. ICRP, Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values (Pergammon, 2003).
34. M. Cremonesi, M. Ferrari, L. Bodei, G. Tosi, and G. Paganelli, Dosimetry in Peptide radionuclide receptor therapy: A review., J. Nucl. Med. 47, 1467-1475 (2006).
35. S. Baechler, R. F. Hobbs, H. A. Jacene, F. O. Bochud, R. L. Wahl, and G. Sgouros, Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab., J. Nucl. Med. 51, 1878-1884 (2010). 10.2967/jnumed.110.079947
36. B. Emami, J. Lyman, A. Brown, L. Coia, M. Goitein, J. E. Munzenrider, B. Shank, L. J. Solin, and M. Wesson, Tolerance of normal tissue to therapeutic irradiation., Int. J. Radiat. Oncol., Biol. Phys. 21, 109-122 (1991). 10.1016/0360-3016(91)90171-Y
37. L. Bodei, M. Cremonesi, C. Grana, P. Rocca, M. Bartolomei, M. Chinol, and G. Paganelli, Receptor radionuclide therapy with 90Y-DOTA0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours., Eur. J. Nucl. Med. Mol. Imaging 31, 1038-1046 (2004). 10.1007/s00259-004-1571-4
38. D. Bushnell, T. O'Dorisio, Y. Menda, T. Carlisle, P. Zehr, M. Connolly, M. Karwal, S. Miller, S. Parker, and H. Bouterfa, Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors., J. Nucl. Med. 44, 1556-1560 (2003).
39. R. Barone, S. Walrand, M. Konijnenberg, R. Valkema, L. K. Kvols, E. P. Krenning, S. Pauwels, and F. Jamar, Therapy using labelled somatostatin analogues: Comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide., Nucl. Med. Commun. 29, 283-290 (2008). 10.1097/MNM.0b013e3282f3d03e
40. F. Forrer, E. P. Krenning, P. P. Kooij, B. F. Bernard, M. Konijnenberg, W. H. Bakker, J. J. Teunissen, M. de Jong, K. van Lom, W. W. de Herder, and D. J. Kwekkeboom, Bone marrow dosimetry in peptide receptor radionuclide therapy with 177Lu-DOTA(0),Tyr(3)octreotate., Eur. J. Nucl. Med. Mol. Imaging 36, 1138-1146 (2009). 10.1007/s00259-009-1072-6
41. S. Pauwels, R. Barone, S. Walrand, F. Borson-Chazot, R. Valkema, L. K. Kvols, E. P. Krenning, and F. Jamar, Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs., J. Nucl. Med. 46 (Suppl. 1), 92S-98S (2005).
42. G. J. Forster, M. J. Engelbach, J. J. Brockmann, H. J. Reber, H. G. Buchholz, H. R. Macke, F. R. Rosch, H. R. Herzog, and P. R. Bartenstein, Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: Comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide., Eur. J. Nucl. Med. 28, 1743-1750 (2001). 10.1007/s002590100628
43. A. Helisch, G. J. Forster, H. Reber, H. G. Buchholz, R. Arnold, B. Goke, M. M. Weber, B. Wiedenmann, S. Pauwels, U. Haus, H. Bouterfa, and P. Bartenstein, Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours., Eur. J. Nucl. Med. Mol. Imaging 31, 1386-1392 (2004). 10.1007/s00259-004-1561-6
44. D. Minarik, K. Sjogreen-Gleisner, O. Linden, K. Wingardh, J. Tennvall, S. E. Strand, and M. Ljungberg, 90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy., J. Nucl. Med. 51, 1974-1978 (2010). 10.2967/jnumed.110.079897
45. X. Rong, Y. Du, M. Ljungberg, E. Rault, S. Vandenberghe, and E. C. Frey, Development and evaluation of an improved quantitative 90Y bremsstrahlung SPECT method., Med. Phys. 39, 2346-2358 (2012). 10.1118/1.3700174
46. M. De Jong, R. Valkema, A. Van Gameren, H. Van Boven, A. Bex, E. P. Van De Weyer, J. D. Burggraaf, M. Korner, J. C. Reubi and E. P. Krenning, Inhomogeneous localization of radioactivity in the human kidney after injection of (111)In-DTPAoctreotide., J. Nucl. Med. 45, 1168-1171 (2004).
47. M. Konijnenberg, M. Melis, R. Valkema, E. Krenning, and J. M. de, Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases., J. Nucl. Med. 48, 134-142 (2007).
48. M. de Jong, W. A. Breeman, R. Valkema, B. F. Bernard, and E. P. Krenning, Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs., J. Nucl. Med. 46 (Suppl. 1), 13S-17S (2005).